Aktuelle Veröffentlichungen

Marian Weiss, Johannes Patrick Frohnmayer, Lucia Theresa Benk, Barbara Haller, Jan-Willi Janiesch, Thomas Heitkamp, Michael Börsch, Rafael B. Lira, Rumiana Dimova, Reinhard Lipowsky, Eberhard Bodenschatz, Jean-Christophe Baret, Tanja Vidakovic-Koch, Kai Sundmacher, Ilia Platzman, Joachim P. Spatz

Axel von Kamp und Steffen Klamt
Growth-coupled overproduction is feasible for almost all metabolites in five major production organisms
Nature Communications 8, 15926, 22. Juni 2017.
DOI: 10.1038/ncomms15956

Antonio Sorrentino, Tanja Vidakovic-Koch, Richard Hanke-Rauschenbach, Kai Sundmacher
Concentration-alternating frequency response: A new method for studying polymer electrolyte membrane fuel cell dynamics
Electrochimica Acta, Volume 243, 20. Juli 2017, pp. 53-64.
DOI: 10.1016/j.electacta.2017.04.150

Non-equimolar discrete compounds in binary chiral systems of organic substances
CrystEngComm, 2017,19, 1851-1869.
DOI: 10.1039/C6CE02209J
Open Access Article

Peter Benner , Albert Cohen, Mario Ohlberger, und Karen Willcox (Eds.)
Model Reduction and Approximation: Theory and Algorithms
SIAM Publications, Philadelphia, PA, 2017.

Peter Benner
System Reduction for Nanoscale IC Design
Springer International Publishing AG. 2017.
DOI: 10.1007/978-3-319-07236-4

Zu ausgewählten Publikationen ...

Veranstaltungen

WILLKOMMEN IN SACHSEN-ANHALT

Willkommen am Max-Planck-Institut Magdeburg

Nachrichten

Kolloquium

1948 1447321899

MPI Kolloquiumsreihe: Plant-Based Biopharmaceuticals: How to Move New Product Candidates Towards Translational Research and Market

The development of recombinant antibodies and vaccines has allowed us to treat and prevent a large number of life-threatening diseases. However, as things stand in 2015, the speed, capacity and scalability of current production systems is beginning to place limitations on this crucial technology. The large-scale production of antibodies, vaccines and other pharmaceutical recombinant proteins is restricted by the industry’s current reliance on fermenter technology, particularly the culture of mammalian cells. This expensive and time-consuming production platform is preventing the distribution of recombinant protein drugs to those most in need. One way in which the above limitations can be addressed is through the use of plants and plant-based expression systems for rapid recombinant pharmaceutical protein production. The economic production of plant-based pharmaceuticals depends on satisfactory yields and product quality. This presentation will discuss the latest development in antibody and vaccine development and their production by molecular farming, focusing particularly on strategies to maximize protein yields during upstream production and optimize protein recovery in the downstream processing steps. Such strategies often involve careful consideration of how the protein is expressed and targeted within the plant cell, a factor which affects yield, stability, quality and ease of isolation. Our long-term objective is to ensure that next generation of plantbased production systems for recombinant proteins will create the opportunity to deliver antibodies, vaccines and other biopharmaceuticals beyond the industrialized nations and into the developing world. Several case studies will be presented: HIV antibodies were chosen to undergo fast-track development, including risk assessment, expression in tobacco, scale-up, downstream processing and regulatory development, with the aim of performing clinical trials. In addition use of engineered plant cells for human vaccine candidates will be discussed. Pharma-Planta is an EU Sixth Framework Integrated Project whose primary goal is to develop an approved production pipeline for plant-derived pharmaceutical proteins (PDPs). Although previous research has provided proof of the PDP concept, Pharma-Planta aims to develop an entire production chain by taking candidate pharmaceutical molecules from the expression platform through all stages of production and processing, ultimately to initiate phase I human trials in Europe. The Pharma-Planta Consortium comprised 40 interacting groups representing 33 public institutes and SMEs from 11 European Member States and South Africa. At the beginning of the project, eight target molecules were chosen representing four key indication areas including HIV. From these molecules, two HIV antibodies were chosen to undergo fast-track development, which would include risk assessment, cloning, expression and optimization of production in plants, scale-up, downstream processing and regulatory development, with the aim of submitting at least one of them for clinical trials within the five years of the program. Two HIV neutralizing antibodies have been expressed successfully in the two main production crops being developed within the consortium – maize and tobacco. One of these antibodies, 2G12, has been expressed at levels greater 100 mg per kg of plant material. The plant-derived antibodies remain stable and functional and retain their neutralizing activity. The consortium has investigated novel upscaling and downstream processing strategies to provide multiple grams clinical grade antibody material for human clinical trials. Preclinical trials in rabbits have been completed successfully and we also conducted successfully a phase I clinical trial in the UK. This work will now be moved forward for a phase IIa clinical trial which is funded by an Advanced ERC grant from the European Commission. We have also developed an interesting multi-stage malaria vaccine and neutralizing rabies antibody candidates and will discuss how both products have matured over the years both in performance and in manufacturing with the aim in mind to bring these two products into translational research within the next months. Finally state of the art technology developments to accelerate the development and production of PMPs as well as regulatory issues will be discussed. Along this line an innovative new manufacturing concept using LED lighting in a vertical farm concept have been developed. [mehr]

Vortrag im Rahmen der Hybrid Modeling Summer School

2413 1441723591

Synthetic Biology and delivering on, From Gene to Product

Abstract: To some people we may be entering the period of the ‘Fourth Industrial Revolution’ - the Biological Industrial Revolution. Just as in previous industrial revolutions the potential previously promised by coal, mechanisation and electronics has now to be realised by the exploitation of biological potential. This new potential is made available by large scale gene synthesis and expression and understanding the options available for the scale-up and control of novel genetic entities. It seems that in order to start to understand fully how the exploitation of novel biological potential may be realised there needs to be a recognition of the scale and complexity of the task. Novel methodologies in numerical analysis and experimental design as well as in automation and bioprocess engineering need to be employed and coordinated in order to gain commercial traction on synthetic biology. This short talk will seek to identify how techniques of large scale experimental design, scale up and analyses, as well as a novel approach to biological automation are seeking to address just some of the issues surrounding Synthetic Biology and delivering on ‘From Gene to Product’. Short biography of Mr. Craig JL Gershater: Craig is a senior scientist and manager with over 40 years’ industrial bioprocess optimisation and biotechnology experience. He has held a variety of senior positions in the pharmaceutical industry, lastly as Head of Fermentation Sciences R&D at SmithKline Beecham prior to becoming the CEO and Principal Consultant with Cambridge Bioprocess Management Ltd in 2000. Among his many transnational clients in recent years he has worked with GSK, as well as a number of SMEs and in academia. He is an expert in the application of statistical methods to experimental design and rapid bioprocess optimisation. He has used these techniques in a wide variety of industrial research and development projects including full scale development of biotechnology projects to GMP/GLP requirements. [mehr]

Homogeneous Catalytic In-Situ Spectroscopic Measurements and Chemometrics - An Overview of Activities at the National Laboratories in Singapore (A*STAR)

Symposium on Advances and Applications in Metaproteomics

DECHEMA Kolloquium: Continuous Synthesis: Old Concept - New Applications

3552 1447323304

DECHEMA Kolloquium: Continuous Manufacturing: Old Concept - New Applications

The large scale production of bulk chemicals is performed in the chemical process industry frequently applying continuously operated reaction and separation processes. In the fields of “Flow chemistry” and “Continuous Manufacturing” there are currently significant efforts to apply similar principles for the production of fine chemicals and pharmaceuticals, which is traditionally based on batch processes. The current status will be discussed and similarities and differences between the two fields will be highlighted. [mehr]

Vortrag: Processing of functional nanoparticles: From automated synthesis to tailored surface properties and applications

5093 1458287812

Vortrag: Processing of functional nanoparticles: From automated synthesis to tailored surface properties and applications

[mehr]

Kolloquium

4464 1455806910

MPI Kolloquiumsreihe: Life Cycle of Artemisinin: from extraction to derivatisation and drug activity

Dieser Vortrag ist Teil der Kolloquiumsreihe am Max-Planck-Institut Magdeburg. Alle Interessierten sind herzlich eingeladen. [mehr]

A Fast Solver for a Nonsmooth Optimization problem in a phase separation model

Promotionskolloquium: Model Order Reduction for Parameterized Nonlinear Evolution Equations

Promotionskolloquium: Low-Rank Iterative Solvers for Large-Scale Stochastic Galerkin Linear Systems

Promotionskolloquium: Numerical Aspects of Flow Stabilization by Riccati Feedback

Promotionskolloquium: Balancing Related Model Order Reduction Applied to Linear Controlled Evolution Equations with Lévy Noise

Promotionskolloquium: Reduced Basis Approximations for Electromagnetic Applications

Promotionskolloquium: Continuous Preferential Crystallization of Enantiomers: Simulation, Analysis, Process Design and Experimental Validation

Promotionskolloquium: The Structural Dynamics of Soluble and Membrane Proteins Explored through Molecular Simulations

Promotionskolloquium: Etablierung und Anwendung einer durchflusszytometrischen Methode für die Vitalitätsbestimmung von P. aeruginosa, B. cepacia und S. aureus in Mischkulturen

Promotionskolloquium: Novel Computational Methods for the Analysis and Interpretation of MS/MS Data in Metaproteomics

Toward a more sustainable chemical industry: terpenes and arylpropenoids as feedstock in transition metal complex catalyzed reactions

Promotionskolloquium: Modellbasierte Bestimmung von Interventionsstrategien zur Optimierung der Produktion von Biokraftstoffen in Cyanobakterien

Entropic enzymes: The thermodynamics of polymer metabolism

MPI Kolloquiumsreihe: Prof. Dr. Walter Stahel: Opportunity and Risk - Two Sides of Systems' Solutions

Ehrenkolloquium für Prof. Dietrich Flockerzi

Prof. Dr. Herbert Sixta: Fractionation and Valorization of Biomass

8391 1484663437

Prof. Dr. Herbert Sixta: Fractionation and Valorization of Biomass

[mehr]

MPI Kolloquiumsreihe: Prof. Jean-Michel Coron, Stabilization of control systems: From the clepsydras to the regulation of the rivers La Sambre and La Meuse

ENTFÄLLT: MPI Kolloquiumsreihe: Prof. Dr. Rainer Fischer

6690 1485518233

ENTFÄLLT: MPI Kolloquiumsreihe: Prof. Dr. Rainer Fischer

[mehr]

MPI Kolloquiumsreihe: Prof. Dr. Jan-Dierk Grunwaldt, Challenges in Environmental and Energy-related Catalysis: Understanding Catalysts under Dynamic Reaction Conditions

8340 1488285320

MPI Kolloquiumsreihe: Prof. Dr. Jan-Dierk Grunwaldt, Challenges in Environmental and Energy-related Catalysis: Understanding Catalysts under Dynamic Reaction Conditions

[mehr]

Industry Career Workshop “From academia to industry: applied research and career challenges”

MPI Kolloquiumsreihe: Prof. Martha Grover, Crystallization Control using Dynamic Programming

5944 1488468414

MPI Kolloquiumsreihe: Prof. Martha Grover, Crystallization Control using Dynamic Programming

[mehr]

Schülerpraktikum "Verfahrenstechnik und Technische Kybernetik" Ostern 2017

MPI Kolloquiumsreihe: Prof. Dr. Philip Tinnefeld, DNA in new roles: Tools for Superresolution and Nanobiotechnology

8345 1491492267

MPI Kolloquiumsreihe: Prof. Dr. Philip Tinnefeld, DNA in new roles: Tools for Superresolution and Nanobiotechnology

[mehr]

Prof. Dr. Joris Thybaut, Microkinetic modeling: a strategy to govern the phenomena from the active site to the chemical reactor

Dr. Matthias Thommes: Recent Advances in the Textural Characterization of Hierarchically Structured Nanoporous Materials

ENTFÄLLT MPI Kolloquiumsreihe: Prof. Dr. Wolfgang Wiechert, From wild type microbes to industrial chassis organisms

Promotionskolloquium: Investigation of influenza virus particle aggregation and purification with magnetic sulfated cellulose particles

MPI Kolloquiumsreihe: Prof. Dr. Athanasios C. Antoulas, Data-driven model reduction of large-scale systems

6688 1494856629

MPI Kolloquiumsreihe: Prof. Dr. Athanasios C. Antoulas, Data-driven model reduction of large-scale systems

[mehr]

MPI Kolloquiumsreihe: Prof. Dr. Katalin M. Hangos, Dynamics and stabilizing control of nonlinear process networks

9998 1496755567

MPI Kolloquiumsreihe: Prof. Dr. Katalin M. Hangos, Dynamics and stabilizing control of nonlinear process networks

[mehr]

Startup Engineering: Introduction to the Lean-Startup Method

MPI Kolloquiumsreihe: Prof. Dr. Ulrich Pöschl, Multiphase Chemical Kinetics at the Interface of Earth and Life Sciences

8883 1502463717

MPI Kolloquiumsreihe: Prof. Dr. Ulrich Pöschl, Multiphase Chemical Kinetics at the Interface of Earth and Life Sciences

[mehr]

From Mathematics to Chemistry: A nontoxic pain killer designed by modeling of pathological receptor conformations

Schülerpraktikum "Verfahrenstechnik und Technische Kybernetik" Herbst 2017

MPI Colloquia Series: Prof. Dr. Peter H. Seeberger, Preventing and Fighting Infectious Diseases: Carbohydrate Vaccines and Flow Chemistry

9823 1506412720

MPI Kolloquiumsreihe: Prof. Dr. Peter H. Seeberger, Preventing and Fighting Infectious Diseases: Carbohydrate Vaccines and Flow Chemistry

[mehr]

3. MAXNET Energy Workshop

11184 1507127539

3. MAXNET Energy Workshop

[mehr]

MPI Kolloquiumsreihe: Prof. Dr. Gene Myers, Computational Optics and Bioimage Informatics

9642 1492527068

MPI Kolloquiumsreihe: Prof. Dr. Gene Myers, Computational Optics and Bioimage Informatics

[mehr]

Schülerpraktikum "Verfahrenstechnik und Technische Kybernetik" 2018

 
loading content